JPH0466453B2 - - Google Patents

Info

Publication number
JPH0466453B2
JPH0466453B2 JP60016085A JP1608585A JPH0466453B2 JP H0466453 B2 JPH0466453 B2 JP H0466453B2 JP 60016085 A JP60016085 A JP 60016085A JP 1608585 A JP1608585 A JP 1608585A JP H0466453 B2 JPH0466453 B2 JP H0466453B2
Authority
JP
Japan
Prior art keywords
cells
cancer
differentiation
present
anticancer agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60016085A
Other languages
English (en)
Japanese (ja)
Other versions
JPS61176523A (ja
Inventor
Teruhiko Betsupu
Yasushi Iwamoto
Minoru Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP60016085A priority Critical patent/JPS61176523A/ja
Priority to US06/821,973 priority patent/US4690918A/en
Priority to EP86101047A priority patent/EP0196415B1/en
Priority to DE8686101047T priority patent/DE3682091D1/de
Publication of JPS61176523A publication Critical patent/JPS61176523A/ja
Publication of JPH0466453B2 publication Critical patent/JPH0466453B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP60016085A 1985-01-30 1985-01-30 制癌剤 Granted JPS61176523A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP60016085A JPS61176523A (ja) 1985-01-30 1985-01-30 制癌剤
US06/821,973 US4690918A (en) 1985-01-30 1986-01-24 Use of trichostatin compounds for treating tumor cells
EP86101047A EP0196415B1 (en) 1985-01-30 1986-01-27 Trichostatins a and c as antitumour drugs
DE8686101047T DE3682091D1 (de) 1985-01-30 1986-01-27 Trichostatine a und c als antikrebsmittel.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60016085A JPS61176523A (ja) 1985-01-30 1985-01-30 制癌剤

Publications (2)

Publication Number Publication Date
JPS61176523A JPS61176523A (ja) 1986-08-08
JPH0466453B2 true JPH0466453B2 (enExample) 1992-10-23

Family

ID=11906699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60016085A Granted JPS61176523A (ja) 1985-01-30 1985-01-30 制癌剤

Country Status (4)

Country Link
US (1) US4690918A (enExample)
EP (1) EP0196415B1 (enExample)
JP (1) JPS61176523A (enExample)
DE (1) DE3682091D1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0775593A (ja) * 1993-09-08 1995-03-20 Suntory Ltd 蛋白質の製造方法
EP0827946A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Inhibitors for the differentiation of cells, in particular hepatic stellate cells
DK0969822T3 (da) * 1996-12-30 2003-07-21 Univ Johns Hopkins Med Bestemmelse af et organs eller vævs tilbøjelighed til cancer ved bestemmelse af dets prægningsmønster
EP1332756A3 (en) * 1996-12-30 2003-12-10 The Johns Hopkins University School Of Medicine Compositions and methods for restoring a normal pattern of imprinting to cells
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6518012B1 (en) 1999-04-02 2003-02-11 Health Research, Inc. Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation
US6544957B2 (en) 2000-01-04 2003-04-08 The Johns Hopkins University Methods and reagents for facilitating transcription
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) * 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
DE60113645T2 (de) * 2001-04-10 2006-07-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2002102981A2 (en) * 2001-06-15 2002-12-27 The Trustees Of Columbia University In The City Of New York SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
AU2002340253C1 (en) * 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US20030147813A1 (en) * 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
US20030170299A1 (en) * 2002-02-27 2003-09-11 Lee Robert J. Therapeutic methods for acute myeloid leukemia
CN101259120B (zh) * 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
SI2238982T1 (sl) * 2003-06-27 2013-01-31 Astellas Pharma Inc. Terapevtsko sredstvo za mehkotkivni sarkom
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
SI1663194T1 (sl) * 2003-08-26 2010-08-31 Merck Hdac Res Llc Uporaba SAHA za zdravljenje mezotelioma
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US7875275B2 (en) * 2004-06-16 2011-01-25 The General Hospital Corporation Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) * 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
AU2006283677A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer
US20070117776A1 (en) * 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
US20070105792A1 (en) * 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
JP2007262058A (ja) * 2006-03-03 2007-10-11 Tokyo Univ Of Science 糸状菌の分化抑制剤
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
EP2073812A4 (en) * 2006-09-29 2012-08-08 Univ Illinois HISTONACETYL TRANSFERASE ACTIVATORS AND HISTONACETYL DEACETYLASE INHIBITORS IN THE TREATMENT OF ALCOHOLISM
CN101528037A (zh) * 2006-11-03 2009-09-09 默克公司 使用saha和硼替佐米治疗多发性骨髓瘤的方法
CA2676422C (en) 2007-02-06 2018-10-16 Lixte Biotechnology Holdings, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8043804B2 (en) * 2007-05-23 2011-10-25 The Trustees Of Columbia University In The City Of New York DBC1, a novel native inhibitor of anti-aging protein SIRT1
US20090035292A1 (en) * 2007-08-03 2009-02-05 Kovach John S Use of phosphatases to treat neuroblastomas and medulloblastomas
EA018618B1 (ru) * 2007-10-01 2013-09-30 Ликсте Байотекнолоджи, Инк. Ингибиторы hdac
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
CA2730148C (en) 2008-08-01 2018-04-03 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
EP2309853A4 (en) * 2008-08-01 2012-04-25 Lixte Biotechnology Inc METHOD FOR CELL MITITULATING BY INHIBITION OF SERIN / THREONINE PHOSPHATASE
US8227473B2 (en) * 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
EP3431142B1 (en) 2011-08-30 2020-06-17 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
EP2983661B1 (en) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
EP3616754A1 (en) 2013-08-22 2020-03-04 Vanda Pharmaceuticals Inc. Cancer treatment
KR20210021602A (ko) * 2013-08-22 2021-02-26 반다 파마슈티칼즈, 인코퍼레이티드. 다발성 골수종 치료
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
MX2019006694A (es) 2016-12-08 2019-08-21 Lixte Biotechnology Inc Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
RU2020108580A (ru) 2017-08-03 2021-09-03 Оцука Фармасьютикал Ко., Лтд. Лекарственное соединение и способы его очистки

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) * 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
JPS60149520A (ja) * 1984-01-13 1985-08-07 Ajinomoto Co Inc 抗腫瘍剤

Also Published As

Publication number Publication date
EP0196415A2 (en) 1986-10-08
JPS61176523A (ja) 1986-08-08
EP0196415A3 (en) 1988-09-07
US4690918A (en) 1987-09-01
EP0196415B1 (en) 1991-10-23
DE3682091D1 (de) 1991-11-28

Similar Documents

Publication Publication Date Title
JPH0466453B2 (enExample)
US5244922A (en) Methods for treating viral infections
KR100196368B1 (ko) 아폽토시스 조정제
JP4057648B2 (ja) 造血前駆細胞の増殖を促進するチオール類
Chu et al. Paeoniflorin attenuates schistosomiasis japonica-associated liver fibrosis through inhibiting alternative activation of macrophages
RU2197984C1 (ru) Способ лечения различных форм туберкулеза легких, в том числе резистентных к противотуберкулезной химиотерапии
WO2023097764A1 (zh) 青蒿素在靶向抑制髓系来源的抑制性细胞及其在制备肿瘤免疫治疗药物中的应用
CN117159525B (zh) Cert抑制剂在制备治疗急性髓系白血病的药物中的应用
CN111803482A (zh) 鹿茸单体在制备抑制乳腺肿瘤骨转移的药物中的应用及药物
EP0476391B1 (en) Anti-AIDS virus composition containing cepharanthine as active compound
De Fabritiis et al. In vitro pharmacological purging of human bone marrow is enhanced by the use of lonidamine
RU2784809C2 (ru) Комбинированный продукт, содержащий дициклоплатин, и способ его получения и применения
US5750529A (en) Apoptosis regulating compostion
CN118236361A (zh) 牛磺酸联合化疗药物在制备抗肿瘤药物中的应用
CN117442738A (zh) 一种联合用药物组合物在制备预防或治疗t细胞淋巴瘤的药物中的应用
CN108403701B (zh) 二氢雷公藤红素在制备预防或治疗血液肿瘤疾病的药物中的用途
RU2038083C1 (ru) Противовирусное средство
JP2002128690A (ja) アポトーシス誘導剤
CN116036126A (zh) 一种抗肿瘤的药物组合物及其应用
JPS63107924A (ja) 抗レトロウイルス剤
JPS63267718A (ja) 抗腫瘍剤
WO1994013786A1 (en) Novel granulocytic precursor cell growth factor and method
HK1014499B (en) Methods for treating viral infections
HK1004469B (en) Apoptosis regulator
MXPA97006255A (en) Tioles to promote the growth of progenitor cells hematopoyeti